The Ohio State University Comprehensive Cancer Center has hired a new deputy director, a top cancer researcher from Georgetown University.
Dr. Peter Shields‘s primary research focus has been in identifying biomarkers that can be used to assess breast and lung cancer risks, particularly those related to diet, smoking and lifestyle, according to a statement from the Ohio State University Medical Center. A biomarker is a protein found in the blood that can indicate the presence or severity of a certain disease.
“The more markers we identify, the more aggressive screening and monitoring we can do for people with those markers, and we can also focus better our behavioral interventions and chemoprevention,” Shields said.
Behavioral Health, Interoperability and eConsent: Meeting the Demands of CMS Final Rule Compliance
In a webinar on April 16 at 1pm ET, Aneesh Chopra will moderate a discussion with executives from DocuSign, Velatura, and behavioral health providers on eConsent, health information exchange and compliance with the CMS Final Rule on interoperability.
Shields was recently named the president of the American Society of Preventive Oncology and has published more than 180 studies.
At OSU, he’ll oversee the cancer center’s research program, which includes more than 270 cancer researchers from 11 of OSU’s 14 colleges.
In addition to the deputy director role, Shields will also be a professor in OSU’s department of internal medicine.
At Georgetown, Shields was deputy director of the Lombardi Comprehensive Cancer Center.
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
